Status:
UNKNOWN
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
Lead Sponsor:
University of Athens
Conditions:
Hematopoietic Stem Cell Transplantation
Cardiotoxicity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of the present study is to investigate the effect of ACE inhibitors and the sacubitril-valsartan complex in bone marrow transplant patients by assessing cardiovascular and endothelial para...
Detailed Description
The purpose of the present study is to investigate the effect of ACE inhibitors and the sacubitril-valsartan complex in bone marrow transplant patients in preventing cardiotoxicity when administered i...
Eligibility Criteria
Inclusion
- Adolescents male and female
- that have just been treated with bone marrow transplantation due to haematological malignancies.
Exclusion
- Coronary Artery Disease
- Permanent Atrial Fibrilation
- Signs of Left Ventricular Hypertrophy on electrocardiography or echocardiography
- Left ventricle Ejection Fraction\<50% or segmental wall motion abnormalities of left ventricle
- More than moderate valvular disease
- Primary Myocardiopathy
- Blood Pressure\<90 mmHg
- GFR\<30 ml/min/1,73m2
- Unwilling to recruit
- Uncontrolled Arterial hypertension
Key Trial Info
Start Date :
September 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04092309
Start Date
September 20 2019
End Date
September 1 2021
Last Update
April 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Attikon" University General Hospital
Athens, Attica, Greece, 12462